晚期前列腺癌中的芳香化酶抑制：初步交流。

Aromatase inhibition in advanced prostatic cancer: preliminary communication.

作者信息

Shearer R J, Davies J H, Dowsett M, Malone P R, Hedley A, Cunningham D, Coombes R C

机构信息

Department of Urology, St Georges Hospital, Tooting, London, UK.

出版信息

Br J Cancer. 1990 Aug;62(2):275-6. doi: 10.1038/bjc.1990.276.

DOI:10.1038/bjc.1990.276

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1971817/

Abstract

We report the results of the first use of a steroidal aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA, CGP 32349), in the palliation of patients with advanced, hormone resistant, prostatic cancer. Twelve of 19 patients (63%), who had relapsed following castration and other therapies, gained significant pain relief following weekly intramuscular injections of 4-OHA. Five patients (31%) experienced a transient 'tumour flare', represented by an increase in bone pain soon after commencing treatment. The mechanism of action of 4-OHA in palliating patients with advanced prostatic cancer is obscure at present, but may represent an important new treatment modality which may lead to greater insight into prostatic biology.

摘要

我们报告了首次使用甾体类芳香化酶抑制剂4-羟基雄烯二酮（4-OHA，CGP 32349）缓解晚期激素抵抗性前列腺癌患者症状的结果。19例在去势及其他治疗后复发的患者中，12例（63%）在每周肌肉注射4-OHA后疼痛得到显著缓解。5例患者（31%）经历了短暂的“肿瘤flare”，表现为开始治疗后不久骨痛加剧。目前，4-OHA缓解晚期前列腺癌患者症状的作用机制尚不清楚，但可能代表一种重要的新治疗方式，这可能会使我们对前列腺生物学有更深入的了解。

相似文献

1

Aromatase inhibition in advanced prostatic cancer: preliminary communication.晚期前列腺癌中的芳香化酶抑制：初步交流。

Br J Cancer. 1990 Aug;62(2):275-6. doi: 10.1038/bjc.1990.276.

2

Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.芳香化酶抑制作用：4-羟基雄烯二酮（4-OHA，CGP 32349）在晚期前列腺癌中的应用。

Br J Cancer. 1992 Jul;66(1):139-42. doi: 10.1038/bjc.1992.231.

3

Aromatase and other inhibitors in breast and prostatic cancer.芳香化酶及其他抑制剂在乳腺癌和前列腺癌中的应用

J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1043-8. doi: 10.1016/0960-0760(90)90463-u.

4

Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer.在晚期乳腺癌女性中，先用氨鲁米特抑制芳香化酶后，再用4-羟基雄烯二酮抑制芳香化酶。

Breast Cancer Res Treat. 1995 Sep;35(3):249-53. doi: 10.1007/BF00665976.

5

Inhibition of aromatase activity and growth suppression by 4-methoxy-4-androstene-3,17-dione in an androgen sensitive human prostatic carcinoma cell line.4-甲氧基-4-雄烯-3,17-二酮对雄激素敏感的人前列腺癌细胞系芳香化酶活性的抑制及生长抑制作用

Cancer Lett. 1996 Mar 29;101(2):143-8. doi: 10.1016/0304-3835(96)04127-4.

6

Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.用芳香化酶抑制剂4-羟基雄烯二酮治疗绝经后晚期乳腺癌：II期报告。

Cancer Res. 1986 Sep;46(9):4823-6.

7

Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.

J Clin Oncol. 1990 May;8(5):875-80. doi: 10.1200/JCO.1990.8.5.875.

8

Aromatase and its inhibitors in breast cancer treatment--overview and perspective.芳香化酶及其抑制剂在乳腺癌治疗中的应用——综述与展望

Breast Cancer Res Treat. 1994;30(1):1-6. doi: 10.1007/BF00682736.

9

Aromatase inhibitors and hormone-dependent cancers.

J Steroid Biochem Mol Biol. 1990 Nov 20;37(3):327-33. doi: 10.1016/0960-0760(90)90481-y.

10

Aromatase and its inhibitors--an overview.

J Steroid Biochem Mol Biol. 1991;40(1-3):255-61. doi: 10.1016/0960-0760(91)90190-g.

引用本文的文献

1

Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.福美司坦。对其药效学、药代动力学特性以及在乳腺癌和前列腺癌治疗中的潜在应用的综述。

Drugs. 1993 Jan;45(1):66-84. doi: 10.2165/00003495-199345010-00007.

2

Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.芳香化酶抑制作用：4-羟基雄烯二酮（4-OHA，CGP 32349）在晚期前列腺癌中的应用。

Br J Cancer. 1992 Jul;66(1):139-42. doi: 10.1038/bjc.1992.231.

3

Aromatase inhibitors in malignant diseases of aging.芳香化酶抑制剂在衰老相关恶性疾病中的应用

Drugs Aging. 1992 Nov-Dec;2(6):530-45. doi: 10.2165/00002512-199202060-00008.

本文引用的文献

1

Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo.4-羟基-4-雄烯-3,17-二酮和4-乙酰氧基-4-雄烯-3,17-二酮在体外对芳香化酶的失活作用及其在体内的持续效应

Steroids. 1981 Dec;38(6):693-702. doi: 10.1016/0039-128x(81)90087-8.

2

Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma.

J Urol. 1983 Jan;129(1):51-5. doi: 10.1016/s0022-5347(17)51916-3.

3

Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer.晚期前列腺癌对氨鲁米特和醋酸可的松的反应

Br J Cancer. 1984 Dec;50(6):757-63. doi: 10.1038/bjc.1984.253.

4

Failure of human benign prostatic hyperplasia to aromatise testosterone.

J Steroid Biochem. 1982 Jul;17(1):119-20. doi: 10.1016/0022-4731(82)90601-x.

5

4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.4-羟基雄烯二酮治疗绝经后晚期乳腺癌患者

Lancet. 1984 Dec 1;2(8414):1237-9. doi: 10.1016/s0140-6736(84)92795-8.

6

A new oral progestational steroid effective in treating prostatic cancer.

Trans Am Assoc Genitourin Surg. 1966;58:54-62.

7

Is delayed treatment justified in carcinoma of the prostate?

Br J Urol. 1985 Dec;57(6):724-8. doi: 10.1111/j.1464-410x.1985.tb07041.x.

8

Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.芳香化酶抑制剂4-羟基雄烯二酮在绝经后乳腺癌中的应用：治疗剂量和给药途径的优化

Cancer Res. 1987 Apr 1;47(7):1957-61.

9

Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer.

Br J Urol. 1987 Mar;59(3):255-7. doi: 10.1111/j.1464-410x.1987.tb04617.x.

10

The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.氨鲁米特和氢化可的松单独及联合使用对睾丸切除术后前列腺癌患者雄激素水平的影响。

Br J Cancer. 1988 Feb;57(2):190-2. doi: 10.1038/bjc.1988.40.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。